An entirely new approach to targeting disease
Bicycles are a new kind of novel molecule. Their unique structure can deliver high precision to their chosen targets, while their size and surface area means they can potentially engage targets that have historically been resistant to conventional modalities. They are designed to address significant unmet medical needs in patients.
Bicycles are formed by constraining short linear peptides into a stabilized bi-cyclic structure using a central chemical scaffold. This constraint confers attractive drug-like properties, including the potential for high affinity to the designated target. It also allows the peptides in the two loops to adopt biologically relevant secondary and tertiary structures, such as alpha helices and loops – these are features often found in proteins and protein ligands, allowing Bicycles to effectively mimic protein-protein interactions. This, coupled with the large surface area presented by the molecule, will hopefully allow targets that have historically been intractable to small molecules to be readily targeted by Bicycles.
Bicycles are unlike conventional small molecules in that they can be readily conjugated to other chemical payloads, or indeed to other Bicycles, without losing their desired pharmacology. Bicycles combine the pharmacological properties normally associated with a biologic with the pharmacokinetic and synthetic advantages of a small molecule. Their attractive pharmacokinetic properties enable Bicycles to quickly leave the vasculature and distribute rapidly to target tissues and tumors, enabling delivery directly to the required site of action. Here, we believe their pharmacological selectivity to disease associated targets, will allow for the precision guidance of a therapy specifically to the required site of action within the disease tissue.
Short peptides consisting of 9-20 amino acids
Low molecular weight (1.5-2.5kDa), delivering rapid tissue penetration and tuneable PK
Large molecular footprint allowing protein-protein interactions to be targeted
Fully synthetic New Chemical Entities (NCEs)
Ability to multimerize together or conjugate to a range of therapeutic payloads
Renal elimination, potentially minimizing toxicological burden on liver and gut
Scalable and controllable manufacturing using established methodologies